The Quantellect read.As of Nov 19, 2026, 24 active firms cover AbbVie Inc: 20 rate it Buy or better, 4 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $247.00 to $325.00, so the covering firms are broadly aligned. The average target of $291.21 sits 2% above the current $285.93. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 10% this year and 8% next, consensus EPS building from about $3.44 next quarter toward $16.20 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS24 active firms
Buy
Strong Buy00%
Buy2083%
Neutral417%
Sell00%
Strong Sell00%
Based on 24 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$291.21
+1.8% upside
Average target across 19 active firms as of Nov 19, 2026 vs $285.93 current
Highest Target$325.00
Average Target$291.21
Lowest Target$247.00
Detailed analyst forecasts for ABBV
Showing 1–18 of 18 named analysts shown · 24 active firms in the rating projection
As of Nov 19, 2026, 20 of 24 active firms rate ABBV a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ABBV EPS & revenue forecast
EPS · NEXT QUARTER
$3.44
Range $3.31 – $3.90 · 9 analysts · +30% YoY
Next period, 9 analysts expect AbbVie Inc to earn $3.44 a share (range $3.31 – $3.90), versus $2.65 a year earlier. Full-year consensus is $13.98, growing to $16.20 the year after.
REVENUE · NEXT QUARTER
$16.4B
Range $15.9B – $17.2B · 9 analysts · +10% YoY
Revenue is expected to reach $16.4B (range $15.9B – $17.2B), +10.0% year-over-year. Full-year consensus is $67.8B, rising to $73.9B next year.
Top analysts covering AbbVie Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ABBV.
#1
David Amsellem
Piper Sandler · Rank #124
Buy
$303.00+6.0% to target
Overall win rate
50%
+ Follow
#2
Jason Gerberry
B of A Securities · Rank #160
Buy
$319.00+11.6% to target
Overall win rate
47%
+ Follow
#3
Vamil Divan
Guggenheim · Rank #211
Buy
$322.00+12.6% to target
Overall win rate
48%
+ Follow
#4
Terence Flynn
Morgan Stanley · Rank #222
Buy
$346.00+21.0% to target
Overall win rate
36%
+ Follow
#5
CS
Chris Schott
JP Morgan · Rank #287
Buy
$300.00+4.9% to target
Overall win rate
41%
+ Follow
ABBV stock forecast FAQ
What is ABBV's average 12-month price target?+
The 19 active firms with a live target average $291.21 for AbbVie Inc over the next 12 months, ranging from a $325.00 high to a $247.00 low, as of Nov 19, 2026.
Is ABBV stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 24 active firms as of Nov 19, 2026, 20 rate it Buy or Strong Buy, 4 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ABBV?+
The Street-high target is $325.00 (Barclays), and the Street-low is $247.00 (BNP Paribas). The average of all 19 active-firm targets is $291.21.
How many active Wall Street firms cover ABBV?+
24 active firms have a recognized rating on AbbVie Inc as of Nov 19, 2026, and 19 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ABBV?+
Among analysts who currently cover ABBV, David Amsellem of Piper Sandler has the strongest overall Quantellect track record (Rank #124). Their current call is Buy with a $303.00 target.
What is AbbVie Inc's projected EPS for next quarter?+
The consensus estimate is $3.44 per share (range $3.31 – $3.90) across 9 analysts. Full-year EPS is projected at $13.98, rising to $16.20 the following year.
How much revenue is AbbVie Inc expected to report next quarter?+
Consensus revenue is $16.4B (range $15.9B – $17.2B). Full-year revenue is projected at $67.8B, growing to $73.9B next year.
Have analysts been upgrading or downgrading ABBV lately?+
As of Nov 19, 2026, 20 of 24 active firms rate ABBV a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ABBV calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.